Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China
机构：[1]Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Jiangxi, China[2]Department of Gastroenterology, Nanjing First Hospital, Jiangsu, China[3]Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[4]Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China[5]Department of Gastroenterology, Peking University First Hospital, Beijing, China[6]Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Anhui, China[7]Department of Gastroenterology, Qinghai University Affiliated Hospital, Qinghai, China[8]Department of Gastroenterology, First Hospital of Shanxi Medical University, Shanxi, China[9]Department of Gastroenterology, Xiangya Hospital of Central South University, Hunan, China[10]Department of Gastroenterology, Daping Hospital and the Research Institute of Surgery of Third Military Medical University, Chongqing, China[11]Department of Gastroenterology, First Affiliated Hospital of Kunming Medical College, Yunnan, China内科科室外科科室消化内科普通外科普通外一科(胃肠与疝外科)昆明医科大学附属第一医院[12]Department of Gastroenterology, Qilu Hospital of Shandong University, Shandong, China内科科室外科科室消化内科普通外科普通外一科(胃肠与疝外科)昆明医科大学附属第一医院云南省第一人民医院[13]Department of Gastroenterology, Guangzhou First People’s Hospital, Guangdong, China[14]Department of Gastroenterology, Jiangsu Province Hospital, Jiangsu, China江苏省人民医院[15]Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China江苏省人民医院[16]Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China吉林大学中日联谊医院
BackgroundThe efficacy of Helicobacter pylori (H.pylori) eradication has steadily declined, primarily because of antibiotic resistance. This study aimed to evaluate the efficacy and safety of furazolidone eradication therapies as initial treatments for H.pylori infection. MethodsA national, multicenter, open-label, randomized controlled trial was performed at 16 sites across 13 provinces in China to evaluate the efficacy and safety of furazolidone-containing therapies for H.pylori infection. Treatment naive patients were randomly assigned to: esomeprazole 20mg, bismuth 220mg, amoxicillin 1000mg, and furazolidone 100mg twice daily for 10 and 7days (FAB 10 and FAB 7; the same therapy without bismuth (FA 10 and FA 7). The primary and secondary outcomes were the eradication rate and regimen safety, respectively. Treatment success was assessed by the C-13 urea breath test at least 4weeks after treatment completion. ResultsOverall, according to intention-to-treat (ITT) analysis, the eradication rates for FAB 10 and FAB 7 were 86.6% (95% confidence interval [CI], 79.9%-93.2%) and 83.6% (95% CI, 76.3%-90.9%) and for FA 10 and FA 7 were 82.4% (95% CI, 74.9%-89.8%) and 77.6% (95% CI, 69.4%-85.8%), respectively. According to per-protocol analysis, the overall eradication rates for FAB 10 and FAB 7 were 94.7% (95% CI, 90.3%-99.1%) and 90.8% (95% CI, 85.1%-96.5%) and for FA 10 and FA 7 were 90.6% (95% CI, 84.9%-96.3%) and 85.1% (95% CI, 78.2%-92.1%), respectively. The overall prevalence of side effects was 8.1%. ConclusionsFurazolidone-containing therapies, particularly the tested 10-day quadruple therapy, exhibited satisfactory efficacy and safety. This 10-day quadruple therapy represents a promising initial treatment strategy for Chinese patients.
基金：
National Key Research and Development Program of China [2016YFC1302201]
第一作者机构：[1]Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Jiangxi, China
共同第一作者：
通讯作者：
通讯机构：[*1]Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.[*2]Department of Gastroenterology, Nanfang Hospital, Guangzhou, Guangdong, China.[*3]Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China
推荐引用方式(GB/T 7714)：
Yong Xie,Zhenyu Zhang,Junbo Hong,et al.Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China[J].HELICOBACTER.2018,23(5):doi:10.1111/hel.12496.
APA：
Yong Xie,Zhenyu Zhang,Junbo Hong,Wenzhong Liu,Hong Lu...&for the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori.(2018).Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China.HELICOBACTER,23,(5)
MLA：
Yong Xie,et al."Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China".HELICOBACTER 23..5(2018)
